- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06689930
Implementação comunitária do STAC
Promoção e prevenção da saúde com base na comunidade, modificando a manutenção da saúde após (por volta) do parto com hipertensão durante a gravidez até o pós-parto
This study is being done to adapt the Staying Healthy After Childbirth (STAC) intervention for implementation among Black Women and Birthing Persons (WBP).
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Hypertensive disorders of pregnancy (HDP) are windows into chronic disease risk. The immediate postpartum (PP) period (6 weeks) is the highest risk and most important period for prevention of serious adverse outcomes with long term consequences. This project focuses on a multicomponent evidence-based intervention, Staying Healthy After Childbirth (STAC) that has been tested in a Midwest academic hospital. The intervention has been shown to be effective at addressing factors associated with health promotion priorities in populations with high levels of health disparities and inequities by increasing access to hypertension (HTN) care in the critical PP window by providing patients a home blood pressure monitor and access to a dedicated healthcare team that provides remote BP surveillance and antihypertensive medication titration. To optimize STAC to prevent and reduce racial disparities in immediate PP morbidity and mortality, deeper engagement with community stakeholders is critical.
This is a qualitative investigation designed as pre-implementation of the Adapted Staying Healthy After Childbirth (A-STAC) intervention.
STAC-Community Advisory Board (CAB) members and Lived Experience Group members will provide qualitative data through semi-structured interviews regarding implementation factors of STAC, including priorities for adaptation, barriers and facilitators to implementation, and usability. Rapid qualitative analysis will be used to glean themes from the qualitative data. A second round of semi-structured focus groups using the nominal decision-making process will be conducted to address the revisions to implementation strategies and determine priorities for A-STAC. Next, abbreviated study cycles to test implementation (Plan-Do-Study-Act or PDSA cycles) will take place, with Community Based Organization (CBO) partners and participating Black pregnant persons. After each PDSA cycle, interviews and surveys with patients and staff will be conducted. Rapid qualitative analysis will again be used to gain information about the usability of A-STAC from the focus group; this information will then be used to refine the A-STAC intervention. This process will be repeated for a second PDSA cycle (up to three PDSA cycles total), after which the A-STAC intervention will be finalized for implementation (registered to a separate ClinicalTrials.gov record).
Step 1: Conduct interviews with STAC-CAB members (8-12 members) and Lived Experience Group members (8-12 members) to evaluate implementation factors and priorities for adaptation of STAC.
Use rapid qualitative analysis process to glean implementation strategies.
Step 2: Conduct small focus groups (3-4 participants per group) with STAC-CAB members (8-12 members) and Lived Experience Group members separately using nominal group decision decision making process.
Address revisions to implementation strategies and priorities for A-STAC.
Step 3: Conduct PDSA cycles and follow-up interviews and surveys for patients (3-5 participants per cycle, 10 total) and CBO staff (at least 2 staff).
Step 4: Incorporate usability data from cycle 1 to refine A-STAC.
Repeat steps 3-4 for additional PDSA cycles (up to 3).
Step 5: Finalize A-STAC Intervention.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53792
- University of Wisconsin
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria (Interviews and Focus Groups):
- Belong to the STAC-CAB or Lived Experience Group
- Aged 18 or older
Inclusion Criteria (CBO Staff):
- Staff of CBO participating in PDSA cycle
- Aged 18 years or older
Inclusion Criteria (PDSA-Cycles):
- Pregnant persons greater than or equal to 24 weeks gestation and prior to delivery or postpartum
- Self-Identify as African American or Black
- Aged 18 years or older
- Capable of providing informed consent in English
- Can follow M•care System use instructions in English
- Have ownership of a functioning and reliable smartphone to upload and use the M•other App
- Interested in preventing or managing blood pressure during pregnancy
Exclusion Criteria (PDSA-Cycles):
- Persistent second or third trimester bleeding at time of enrollment
- Premature rupture of membranes in the current pregnancy at time of enrollment
- Known unrepaired maternal congenital heart disease requiring surgical correction
- Maternal heart failure
- Chronic kidney disease specifically requiring dialysis
- On greater than two antihypertensive medications at time of enrollment
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Sem intervenção: STAC-CAB Members
Staying Healthy After Childbirth - Community Advisory Board members (8-12 members) |
|
|
Sem intervenção: Lived Experience Group Members
Lived Experience Group members (8-12 members) |
|
|
Experimental: PDSA Cycle Participants and CBO Staff
Black pregnant or postpartum persons and Community Based Organization Staff |
Conduct PDSA cycles and follow-up interviews and surveys for patients (3-5 per cycle, 10 total) and CBO staff (no less than 2) |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Qualitative Summary of Barriers to Implementation of A-STAC
Prazo: up to 4 weeks
|
Barriers to implementation of A-STAC in CBOs will be investigated via qualitative analysis of interviews and focus groups with STAC-CAB members. All feedback regarding barriers will be coded for themes summarized by participant count. |
up to 4 weeks
|
|
Qualitative Summary of Facilitators to Implementation of A-STAC
Prazo: up to 4 weeks
|
Facilitators to implementation of A-STAC in CBOs will be investigated via qualitative analysis of interviews and focus groups with STAC-CAB members. All feedback regarding facilitators will be coded for themes summarized by participant count. |
up to 4 weeks
|
|
Qualitative Summary of Adaptations to STAC
Prazo: up to 8 weeks
|
Adaptations to STAC will be analyzed from patient participant interviews and CBO staff participants post-PDSA cycles. Interviews will be coded for themes summarized by count. |
up to 8 weeks
|
|
The Acceptability of Intervention Measure (AIM)
Prazo: up to 8 weeks
|
The Acceptability of Intervention Measure (AIM) measures intervention acceptability with 4 items ranked on a 5-point Likert-type scale from 1 = Completely Disagree to 5 = Completely Agree. Higher scores indicate higher acceptability. |
up to 8 weeks
|
|
The Intervention Appropriateness Measure (IAM)
Prazo: up to 8 weeks
|
The Intervention Appropriateness Measure (IAM) measures intervention appropriateness with 4 items ranked on a 5-point Likert-type scale from 1 = Completely Disagree to 5 = Completely Agree. Higher scores indicate higher acceptability. |
up to 8 weeks
|
|
The Feasibility of Intervention Measure (FIM)
Prazo: up to 8 weeks
|
The Feasibility of Intervention Measure (FIM) measures intervention feasibility with 4 items ranked on a 5-point Likert-type scale from 1 = Completely Disagree to 5 = Completely Agree. Higher scores indicate higher acceptability. |
up to 8 weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Kara Hoppe, DO, PhD, University of Wisconsin, Madison
- Investigador principal: Andrew Garbacz, PhD, University of Wisconsin, Madison
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2024-1594
- U48DP006793 (Concessão/Contrato do NIH dos EUA)
- Protocol Approved 5/14/26 (Outro identificador: UW Madison)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .